

Special Issue

Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases 2.0

Message from the Guest Editors

The importance of vaccination has gained much attention, again, due to the advent of COVID-19 pandemic. Vaccine adjuvants and/or immunomodulators, either directly or indirectly, have become an indispensable component for many (if not all) vaccines, including RNA, DNA, recombinant proteins, inactivated and attenuated, and viral vector vaccines. We invite potential researchers to submit a research article or a comprehensive/mini/ opinion review article related to vaccines and vaccine adjuvants/immunomodulators against infectious diseases. Here you can see our previous Special Issue "Vaccines and Vaccine Adjuvants/Immunomodulators for Infectious Diseases" https://www.mdpi.com/journal/vaccines/special_issues/Adjuvants_Immunomodulators_vaccines

Guest Editors

Prof. Dr. Jagadeesh Bayry

1. INSERM, Centre de Recherche des Cordeliers, Sorbonne Université, F-75006 Paris, France
2. Indian Institute of Technology Palakkad, Kerala 678623, India

Dr. Srinivasa Reddy Bonam

Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA

Deadline for manuscript submissions

closed (31 July 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/132742

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).